Pharmacokinetic and pharmacodynamic aspects of polypeptide delivery
- 1 January 1990
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 11 (1-3), 343-356
- https://doi.org/10.1016/0168-3659(90)90146-k
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A guide to the clinical use of the somatostatin analogue SMS 201-995 (Sandostatin)Acta Endocrinologica, 1987
- Shrinking of a Growth Hormone-Producing Pituitary Tumor by Continuous Subcutaneous Infusion of the Somatostatin Analog SMS 201-995Journal of Clinical Endocrinology & Metabolism, 1987
- CONTINUOUS SUBCUTANEOUS PUMP INFUSION OF SOMATOSTATIN ANALOGUE SMS 201‐995 VERSUS SUBCUTANEOUS INJECTION SCHEDULE IN ACROMEGALIC PATIENTSClinical Endocrinology, 1987
- Hypogonadotropic Disorders in Men and Women: Diagnosis and Therapy with Pulsatile Gonadotropin-Releasing HormoneEndocrine Reviews, 1986
- Pharmacokinetics of SMS 201-995 in Healthy SubjectsScandinavian Journal of Gastroenterology, 1986
- Chemistry and Pharmacology of SMS 201-995, a Long-Acting Octapeptide Analogue of SomatostatinScandinavian Journal of Gastroenterology, 1986
- Somatostatin Octapeptide (SMS 201-995) in the Medical Treatment of AcromegalyScandinavian Journal of Gastroenterology, 1986
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981
- Pituitary and Gonadal Desensitization after Continuous Luteinizing Hormone-Releasing Hormone Infusion in Normal Females*Journal of Clinical Endocrinology & Metabolism, 1980
- Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarineCancer Cell, 1979